ID   IGF1R_HUMAN             Reviewed;        1367 AA.
AC   P08069; B1B5Y2; Q14CV2; Q9UCC0;
DT   01-AUG-1988, integrated into UniProtKB/Swiss-Prot.
DT   01-AUG-1988, sequence version 1.
DT   12-OCT-2022, entry version 243.
DE   RecName: Full=Insulin-like growth factor 1 receptor;
DE            EC=2.7.10.1;
DE   AltName: Full=Insulin-like growth factor I receptor;
DE            Short=IGF-I receptor;
DE   AltName: CD_antigen=CD221;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor alpha chain;
DE   Contains:
DE     RecName: Full=Insulin-like growth factor 1 receptor beta chain;
DE   Flags: Precursor;
GN   Name=IGF1R;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], AND PROTEIN SEQUENCE OF 31-56; 446-453;
RP   503-524; 561-579; 668-672 AND 721-729.
RC   TISSUE=Placenta;
RX   PubMed=2877871; DOI=10.1002/j.1460-2075.1986.tb04528.x;
RA   Ullrich A., Gray A., Tam A.W., Yang-Feng T., Tsubokawa M., Collins C.,
RA   Henzel W., Bon T.L., Kathuria S., Chen E., Jacobs S., Francke U.,
RA   Ramachandran J., Fujita-Yamaguchi Y.;
RT   "Insulin-like growth factor I receptor primary structure: comparison with
RT   insulin receptor suggests structural determinants that define functional
RT   specificity.";
RL   EMBO J. 5:2503-2512(1986).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA].
RX   PubMed=1316909; DOI=10.1016/s0021-9258(19)50083-7;
RA   Abbot A.M., Bueno R., Pedrini M.T., Murray J.M., Smith R.J.;
RT   "Insulin-like growth factor I receptor gene structure.";
RL   J. Biol. Chem. 267:10759-10763(1992).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Fetal brain;
RA   Nagase T., Kikuno R.F., Yamakawa H., Ohara O.;
RL   Submitted (FEB-2008) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND VARIANTS MET-388 AND HIS-605.
RG   NIEHS SNPs program;
RL   Submitted (JUN-2003) to the EMBL/GenBank/DDBJ databases.
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA] OF 1-31.
RX   PubMed=1711844; DOI=10.1016/0006-291x(91)90654-p;
RA   Cooke D.W., Bankert L.A., Roberts C.T. Jr., Leroith D., Casella S.J.;
RT   "Analysis of the human type I insulin-like growth factor receptor promoter
RT   region.";
RL   Biochem. Biophys. Res. Commun. 177:1113-1120(1991).
RN   [8]
RP   PROTEIN SEQUENCE OF 31-45 AND 741-750, FUNCTION, AND FORMATION OF A HYBRID
RP   RECEPTOR WITH INSR.
RC   TISSUE=Placenta;
RX   PubMed=8257688; DOI=10.1021/bi00212a019;
RA   Kasuya J., Paz I.B., Maddux B.A., Goldfine I.D., Hefta S.A.,
RA   Fujita-Yamaguchi Y.;
RT   "Characterization of human placental insulin-like growth factor-I/insulin
RT   hybrid receptors by protein microsequencing and purification.";
RL   Biochemistry 32:13531-13536(1993).
RN   [9]
RP   NUCLEOTIDE SEQUENCE [MRNA] OF 1137-1193, AND TISSUE SPECIFICITY.
RC   TISSUE=Melanocyte;
RX   PubMed=8247543;
RA   Lee S.-T., Strunk K.M., Spritz R.A.;
RT   "A survey of protein tyrosine kinase mRNAs expressed in normal human
RT   melanocytes.";
RL   Oncogene 8:3403-3410(1993).
RN   [10]
RP   FUNCTION, SUBUNIT, AND AUTOPHOSPHORYLATION.
RX   PubMed=1846292; DOI=10.1021/bi00215a008;
RA   Tollefsen S.E., Stoszek R.M., Thompson K.;
RT   "Interaction of the alpha beta dimers of the insulin-like growth factor I
RT   receptor is required for receptor autophosphorylation.";
RL   Biochemistry 30:48-54(1991).
RN   [11]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=8452530; DOI=10.1042/bj2900419;
RA   Soos M.A., Field C.E., Siddle K.;
RT   "Purified hybrid insulin/insulin-like growth factor-I receptors bind
RT   insulin-like growth factor-I, but not insulin, with high affinity.";
RL   Biochem. J. 290:419-426(1993).
RN   [12]
RP   FUNCTION, CATALYTIC ACTIVITY, AND AUTOPHOSPHORYLATION.
RX   PubMed=7679099; DOI=10.1016/s0021-9258(18)53824-2;
RA   Kato H., Faria T.N., Stannard B., Roberts C.T. Jr., LeRoith D.;
RT   "Role of tyrosine kinase activity in signal transduction by the insulin-
RT   like growth factor-I (IGF-I) receptor. Characterization of kinase-deficient
RT   IGF-I receptors and the action of an IGF-I-mimetic antibody (alpha IR-3).";
RL   J. Biol. Chem. 268:2655-2661(1993).
RN   [13]
RP   INTERACTION WITH IRS1; SHC1 AND PIK3R1, MUTAGENESIS OF TYR-980 AND
RP   LYS-1033, AND PHOSPHORYLATION AT TYR-980.
RX   PubMed=7541045; DOI=10.1074/jbc.270.26.15639;
RA   Craparo A., O'Neill T.J., Gustafson T.A.;
RT   "Non-SH2 domains within insulin receptor substrate-1 and SHC mediate their
RT   phosphotyrosine-dependent interaction with the NPEY motif of the insulin-
RT   like growth factor I receptor.";
RL   J. Biol. Chem. 270:15639-15643(1995).
RN   [14]
RP   FORMATION OF A HYBRID RECEPTOR WITH INSR, AND TISSUE SPECIFICITY.
RX   PubMed=9355755; DOI=10.1042/bj3270209;
RA   Bailyes E.M., Nave B.T., Soos M.A., Orr S.R., Hayward A.C., Siddle K.;
RT   "Insulin receptor/IGF-I receptor hybrids are widely distributed in
RT   mammalian tissues: quantification of individual receptor species by
RT   selective immunoprecipitation and immunoblotting.";
RL   Biochem. J. 327:209-215(1997).
RN   [15]
RP   INTERACTION WITH 14-3-3 PROTEINS.
RX   PubMed=9581554; DOI=10.1042/bj3270765;
RA   Furlanetto R.W., Dey B.R., Lopaczynski W., Nissley S.P.;
RT   "14-3-3 proteins interact with the insulin-like growth factor receptor but
RT   not the insulin receptor.";
RL   Biochem. J. 327:765-771(1997).
RN   [16]
RP   FORMATION OF A HYBRID RECEPTOR WITH INSR, AND TISSUE SPECIFICITY.
RX   PubMed=9202395; DOI=10.1016/s0303-7207(97)04050-1;
RA   Federici M., Porzio O., Zucaro L., Fusco A., Borboni P., Lauro D.,
RA   Sesti G.;
RT   "Distribution of insulin/insulin-like growth factor-I hybrid receptors in
RT   human tissues.";
RL   Mol. Cell. Endocrinol. 129:121-126(1997).
RN   [17]
RP   INTERACTION WITH SOCS1 AND SOCS2.
RX   PubMed=9727029; DOI=10.1074/jbc.273.37.24095;
RA   Dey B.R., Spence S.L., Nissley P., Furlanetto R.W.;
RT   "Interaction of human suppressor of cytokine signaling (SOCS)-2 with the
RT   insulin-like growth factor-I receptor.";
RL   J. Biol. Chem. 273:24095-24101(1998).
RN   [18]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=9822622; DOI=10.1074/jbc.273.48.31640;
RA   Lin F.-T., Daaka Y., Lefkowitz R.J.;
RT   "beta-arrestins regulate mitogenic signaling and clathrin-mediated
RT   endocytosis of the insulin-like growth factor I receptor.";
RL   J. Biol. Chem. 273:31640-31643(1998).
RN   [19]
RP   FUNCTION IN CANCER.
RX   PubMed=10579905; DOI=10.1006/excr.1999.4667;
RA   Baserga R.;
RT   "The IGF-I receptor in cancer research.";
RL   Exp. Cell Res. 253:1-6(1999).
RN   [20]
RP   INTERACTION WITH GRB10, AND MUTAGENESIS OF TYR-980; TYR-1280; TYR-1281 AND
RP   TYR-1346.
RX   PubMed=10454568; DOI=10.1128/mcb.19.9.6217;
RA   Wang J., Dai H., Yousaf N., Moussaif M., Deng Y., Boufelliga A.,
RA   Swamy O.R., Leone M.E., Riedel H.;
RT   "Grb10, a positive, stimulatory signaling adapter in platelet-derived
RT   growth factor BB-, insulin-like growth factor I-, and insulin-mediated
RT   mitogenesis.";
RL   Mol. Cell. Biol. 19:6217-6228(1999).
RN   [21]
RP   INTERACTION WITH SOCS3.
RX   PubMed=11071852; DOI=10.1006/bbrc.2000.3762;
RA   Dey B.R., Furlanetto R.W., Nissley P.;
RT   "Suppressor of cytokine signaling (SOCS)-3 protein interacts with the
RT   insulin-like growth factor-I receptor.";
RL   Biochem. Biophys. Res. Commun. 278:38-43(2000).
RN   [22]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=11162456; DOI=10.1006/bbrc.2000.4046;
RA   Lopaczynski W., Terry C., Nissley P.;
RT   "Autophosphorylation of the insulin-like growth factor I receptor
RT   cytoplasmic domain.";
RL   Biochem. Biophys. Res. Commun. 279:955-960(2000).
RN   [23]
RP   FUNCTION IN ACTIVATION OF STAT3.
RX   PubMed=10747872; DOI=10.1074/jbc.m000089200;
RA   Zong C.S., Chan J., Levy D.E., Horvath C., Sadowski H.B., Wang L.H.;
RT   "Mechanism of STAT3 activation by insulin-like growth factor I receptor.";
RL   J. Biol. Chem. 275:15099-15105(2000).
RN   [24]
RP   TISSUE SPECIFICITY.
RX   PubMed=12019176;
RA   Hellawell G.O., Turner G.D., Davies D.R., Poulsom R., Brewster S.F.,
RA   Macaulay V.M.;
RT   "Expression of the type 1 insulin-like growth factor receptor is up-
RT   regulated in primary prostate cancer and commonly persists in metastatic
RT   disease.";
RL   Cancer Res. 62:2942-2950(2002).
RN   [25]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=12138094; DOI=10.1074/jbc.m202766200;
RA   Pandini G., Frasca F., Mineo R., Sciacca L., Vigneri R., Belfiore A.;
RT   "Insulin/insulin-like growth factor I hybrid receptors have different
RT   biological characteristics depending on the insulin receptor isoform
RT   involved.";
RL   J. Biol. Chem. 277:39684-39695(2002).
RN   [26]
RP   INTERACTION WITH RACK1.
RX   PubMed=11884618; DOI=10.1128/mcb.22.7.2345-2365.2002;
RA   Hermanto U., Zong C.S., Li W., Wang L.H.;
RT   "RACK1, an insulin-like growth factor I (IGF-I) receptor-interacting
RT   protein, modulates IGF-I-dependent integrin signaling and promotes cell
RT   spreading and contact with extracellular matrix.";
RL   Mol. Cell. Biol. 22:2345-2365(2002).
RN   [27]
RP   FUNCTION, AND INTERACTION WITH MAP3K5.
RX   PubMed=12556535; DOI=10.1074/jbc.m211398200;
RA   Galvan V., Logvinova A., Sperandio S., Ichijo H., Bredesen D.E.;
RT   "Type 1 insulin-like growth factor receptor (IGF-IR) signaling inhibits
RT   apoptosis signal-regulating kinase 1 (ASK1).";
RL   J. Biol. Chem. 278:13325-13332(2003).
RN   [28]
RP   UBIQUITINATION BY MDM2, AND INTERACTION WITH MDM2.
RX   PubMed=12821780; DOI=10.1073/pnas.1431613100;
RA   Girnita L., Girnita A., Larsson O.;
RT   "Mdm2-dependent ubiquitination and degradation of the insulin-like growth
RT   factor 1 receptor.";
RL   Proc. Natl. Acad. Sci. U.S.A. 100:8247-8252(2003).
RN   [29]
RP   ACTIVITY REGULATION.
RX   PubMed=14729630; DOI=10.1158/0008-5472.can-03-2522;
RA   Girnita A., Girnita L., del Prete F., Bartolazzi A., Larsson O.,
RA   Axelson M.;
RT   "Cyclolignans as inhibitors of the insulin-like growth factor-1 receptor
RT   and malignant cell growth.";
RL   Cancer Res. 64:236-242(2004).
RN   [30]
RP   INTERACTION WITH ARRB1 AND ARRB2.
RX   PubMed=15878855; DOI=10.1074/jbc.m501129200;
RA   Girnita L., Shenoy S.K., Sehat B., Vasilcanu R., Girnita A.,
RA   Lefkowitz R.J., Larsson O.;
RT   "{beta}-Arrestin is crucial for ubiquitination and down-regulation of the
RT   insulin-like growth factor-1 receptor by acting as adaptor for the MDM2 E3
RT   ligase.";
RL   J. Biol. Chem. 280:24412-24419(2005).
RN   [31]
RP   INTERACTION WITH STAT3.
RX   PubMed=15998644; DOI=10.1074/jbc.m501316200;
RA   Yadav A., Kalita A., Dhillon S., Banerjee K.;
RT   "JAK/STAT3 pathway is involved in survival of neurons in response to
RT   insulin-like growth factor and negatively regulated by suppressor of
RT   cytokine signaling-3.";
RL   J. Biol. Chem. 280:31830-31840(2005).
RN   [32]
RP   FUNCTION, AND FORMATION OF A HYBRID RECEPTOR WITH INSR.
RX   PubMed=16831875; DOI=10.1074/jbc.m605189200;
RA   Slaaby R., Schaeffer L., Lautrup-Larsen I., Andersen A.S., Shaw A.C.,
RA   Mathiasen I.S., Brandt J.;
RT   "Hybrid receptors formed by insulin receptor (IR) and insulin-like growth
RT   factor I receptor (IGF-IR) have low insulin and high IGF-1 affinity
RT   irrespective of the IR splice variant.";
RL   J. Biol. Chem. 281:25869-25874(2006).
RN   [33]
RP   SUBCELLULAR LOCATION, AND PROTEOLYTIC PROCESSING.
RX   PubMed=17524361; DOI=10.1016/j.bbrc.2007.05.062;
RA   McElroy B., Powell J.C., McCarthy J.V.;
RT   "The insulin-like growth factor 1 (IGF-1) receptor is a substrate for
RT   gamma-secretase-mediated intramembrane proteolysis.";
RL   Biochem. Biophys. Res. Commun. 358:1136-1141(2007).
RN   [34]
RP   REVIEW ON IGF1R IN CANCER.
RX   PubMed=17624760; DOI=10.1016/j.ejca.2007.05.021;
RA   Hartog H., Wesseling J., Boezen H.M., van der Graaf W.T.;
RT   "The insulin-like growth factor 1 receptor in cancer: old focus, new
RT   future.";
RL   Eur. J. Cancer 43:1895-1904(2007).
RN   [35]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=18691976; DOI=10.1016/j.molcel.2008.07.007;
RA   Daub H., Olsen J.V., Bairlein M., Gnad F., Oppermann F.S., Korner R.,
RA   Greff Z., Keri G., Stemmann O., Mann M.;
RT   "Kinase-selective enrichment enables quantitative phosphoproteomics of the
RT   kinome across the cell cycle.";
RL   Mol. Cell 31:438-448(2008).
RN   [36]
RP   BINDING TO IGF1, AND IDENTIFICATION IN A COMPLEX WITH INTEGRIN AND IGF1.
RX   PubMed=19578119; DOI=10.1074/jbc.m109.013201;
RA   Saegusa J., Yamaji S., Ieguchi K., Wu C.Y., Lam K.S., Liu F.T.,
RA   Takada Y.K., Takada Y.;
RT   "The direct binding of insulin-like growth factor-1 (IGF-1) to integrin
RT   alphavbeta3 is involved in IGF-1 signaling.";
RL   J. Biol. Chem. 284:24106-24114(2009).
RN   [37]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.m800588-mcp200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [38]
RP   SUMOYLATION.
RX   PubMed=20596523; DOI=10.1371/journal.pone.0011332;
RA   Del Rincon S.V., Rogers J., Widschwendter M., Sun D., Sieburg H.B.,
RA   Spruck C.;
RT   "Development and validation of a method for profiling post-translational
RT   modification activities using protein microarrays.";
RL   PLoS ONE 5:E11332-E11332(2010).
RN   [39]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Cervix carcinoma;
RX   PubMed=20068231; DOI=10.1126/scisignal.2000475;
RA   Olsen J.V., Vermeulen M., Santamaria A., Kumar C., Miller M.L.,
RA   Jensen L.J., Gnad F., Cox J., Jensen T.S., Nigg E.A., Brunak S., Mann M.;
RT   "Quantitative phosphoproteomics reveals widespread full phosphorylation
RT   site occupancy during mitosis.";
RL   Sci. Signal. 3:RA3-RA3(2010).
RN   [40]
RP   UBIQUITINATION AT LYS-1168 AND LYS-1171.
RX   PubMed=21994939; DOI=10.1074/jbc.m111.288514;
RA   Mao Y., Shang Y., Pham V.C., Ernst J.A., Lill J.R., Scales S.J., Zha J.;
RT   "Polyubiquitination of insulin-like growth factor I receptor (IGF-IR)
RT   activation loop promotes antibody-induced receptor internalization and
RT   down-regulation.";
RL   J. Biol. Chem. 286:41852-41861(2011).
RN   [41]
RP   BINDING TO IGF1, AND IDENTIFICATION IN A COMPLEX WITH INTEGRIN AND IGF1.
RX   PubMed=22351760; DOI=10.1074/jbc.m111.304170;
RA   Fujita M., Ieguchi K., Davari P., Yamaji S., Taniguchi Y., Sekiguchi K.,
RA   Takada Y.K., Takada Y.;
RT   "Cross-talk between integrin alpha6beta4 and insulin-like growth factor-1
RT   receptor (IGF1R) through direct alpha6beta4 binding to IGF1 and subsequent
RT   alpha6beta4-IGF1-IGF1R ternary complex formation in anchorage-independent
RT   conditions.";
RL   J. Biol. Chem. 287:12491-12500(2012).
RN   [42]
RP   INTERACTION WITH ZFAND2B.
RX   PubMed=26692333; DOI=10.1038/nm.4013;
RA   Osorio F.G., Soria-Valles C., Santiago-Fernandez O., Bernal T.,
RA   Mittelbrunn M., Colado E., Rodriguez F., Bonzon-Kulichenko E., Vazquez J.,
RA   Porta-de-la-Riva M., Ceron J., Fueyo A., Li J., Green A.R., Freije J.M.,
RA   Lopez-Otin C.;
RT   "Loss of the proteostasis factor AIRAPL causes myeloid transformation by
RT   deregulating IGF-1 signaling.";
RL   Nat. Med. 22:91-96(2016).
RN   [43]
RP   INTERACTION WITH HRSV FUSION GLYCOPROTEIN F1/F2 HETERODIMER (MICROBIAL
RP   INFECTION).
RX   PubMed=32494007; DOI=10.1038/s41586-020-2369-7;
RA   Griffiths C.D., Bilawchuk L.M., McDonough J.E., Jamieson K.C., Elawar F.,
RA   Cen Y., Duan W., Lin C., Song H., Casanova J.L., Ogg S., Jensen L.D.,
RA   Thienpont B., Kumar A., Hobman T.C., Proud D., Moraes T.J., Marchant D.J.;
RT   "IGF1R is an entry receptor for respiratory syncytial virus.";
RL   Nature 583:615-619(2020).
RN   [44]
RP   X-RAY CRYSTALLOGRAPHY (2.60 ANGSTROMS) OF 31-492, DISULFIDE BONDS, AND
RP   GLYCOSYLATION AT ASN-51; ASN-135; ASN-244 AND ASN-314.
RX   PubMed=9690478; DOI=10.1038/28668;
RA   Garrett T.P., McKern N.M., Lou M., Frenkel M.J., Bentley J.D.,
RA   Lovrecz G.O., Elleman T.C., Cosgrove L.J., Ward C.W.;
RT   "Crystal structure of the first three domains of the type-1 insulin-like
RT   growth factor receptor.";
RL   Nature 394:395-399(1998).
RN   [45]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 988-1286 IN COMPLEX WITH AMP-PCP
RP   AND PEPTIDE SUBSTRATE, CATALYTIC ACTIVITY, ACTIVE SITE, ACTIVITY
RP   REGULATION, IDENTIFICATION BY MASS SPECTROMETRY, AND PHOSPHORYLATION AT
RP   TYR-1161; TYR-1165 AND TYR-1166.
RX   PubMed=11694888; DOI=10.1038/nsb721;
RA   Favelyukis S., Till J.H., Hubbard S.R., Miller W.T.;
RT   "Structure and autoregulation of the insulin-like growth factor 1 receptor
RT   kinase.";
RL   Nat. Struct. Biol. 8:1058-1063(2001).
RN   [46]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 981-1286 IN COMPLEX WITH ANP,
RP   AUTOPHOSPHORYLATION, ACTIVE SITE, AND IDENTIFICATION BY MASS SPECTROMETRY.
RX   PubMed=11591350; DOI=10.1016/s0969-2126(01)00655-4;
RA   Pautsch A., Zoephel A., Ahorn H., Spevak W., Hauptmann R., Nar H.;
RT   "Crystal structure of bisphosphorylated IGF-1 receptor kinase: insight into
RT   domain movements upon kinase activation.";
RL   Structure 9:955-965(2001).
RN   [47]
RP   X-RAY CRYSTALLOGRAPHY (2.70 ANGSTROMS) OF 974-1294.
RX   PubMed=12138114; DOI=10.1074/jbc.m205580200;
RA   Munshi S., Kornienko M., Hall D.L., Reid J.C., Waxman L., Stirdivant S.M.,
RA   Darke P.L., Kuo L.C.;
RT   "Crystal structure of the Apo, unactivated insulin-like growth factor-1
RT   receptor kinase. Implication for inhibitor specificity.";
RL   J. Biol. Chem. 277:38797-38802(2002).
RN   [48]
RP   X-RAY CRYSTALLOGRAPHY (1.50 ANGSTROMS) OF 974-1294.
RX   PubMed=14501110; DOI=10.1107/s0907444903015415;
RA   Munshi S., Hall D.L., Kornienko M., Darke P.L., Kuo L.C.;
RT   "Structure of apo, unactivated insulin-like growth factor-1 receptor kinase
RT   at 1.5 A resolution.";
RL   Acta Crystallogr. D 59:1725-1730(2003).
RN   [49]
RP   X-RAY CRYSTALLOGRAPHY (2.00 ANGSTROMS) OF 982-1286 IN COMPLEX WITH
RP   BENZIMIDAZOLE PYRIDINONE INHIBITOR, CATALYTIC ACTIVITY, AND ACTIVITY
RP   REGULATION.
RX   PubMed=17317169; DOI=10.1016/j.bmcl.2007.01.102;
RA   Velaparthi U., Wittman M., Liu P., Stoffan K., Zimmermann K., Sang X.,
RA   Carboni J., Li A., Attar R., Gottardis M., Greer A., Chang C.Y.,
RA   Jacobsen B.L., Sack J.S., Sun Y., Langley D.R., Balasubramanian B.,
RA   Vyas D.;
RT   "Discovery and initial SAR of 3-(1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-
RT   ones as inhibitors of insulin-like growth factor 1-receptor (IGF-1R).";
RL   Bioorg. Med. Chem. Lett. 17:2317-2321(2007).
RN   [50]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 981-1286, AND PHOSPHORYLATION AT
RP   TYR-1161; TYR-1165 AND TYR-1166.
RX   PubMed=18501599; DOI=10.1016/j.bmcl.2008.04.044;
RA   Mayer S.C., Banker A.L., Boschelli F., Di L., Johnson M., Kenny C.H.,
RA   Krishnamurthy G., Kutterer K., Moy F., Petusky S., Ravi M., Tkach D.,
RA   Tsou H.R., Xu W.;
RT   "Lead identification to generate isoquinolinedione inhibitors of insulin-
RT   like growth factor receptor (IGF-1R) for potential use in cancer
RT   treatment.";
RL   Bioorg. Med. Chem. Lett. 18:3641-3645(2008).
RN   [51]
RP   X-RAY CRYSTALLOGRAPHY (2.30 ANGSTROMS) OF 986-1286 IN COMPLEX WITH
RP   INHIBITOR PQIP, SUBUNIT, AUTOPHOSPHORYLATION, CATALYTIC ACTIVITY, ACTIVE
RP   SITE, AND ACTIVITY REGULATION.
RX   PubMed=18566589; DOI=10.1038/emboj.2008.116;
RA   Wu J., Li W., Craddock B.P., Foreman K.W., Mulvihill M.J., Ji Q.S.,
RA   Miller W.T., Hubbard S.R.;
RT   "Small-molecule inhibition and activation-loop trans-phosphorylation of the
RT   IGF1 receptor.";
RL   EMBO J. 27:1985-1994(2008).
RN   [52]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 981-1286 IN COMPLEX WITH
RP   3-CYANOQUINOLINE INHIBITOR, CATALYTIC ACTIVITY, ACTIVITY REGULATION, AND
RP   PHOSPHORYLATION AT TYR-1161; TYR-1165 AND TYR-1166.
RX   PubMed=19041240; DOI=10.1016/j.bmcl.2008.11.037;
RA   Miller L.M., Mayer S.C., Berger D.M., Boschelli D.H., Boschelli F., Di L.,
RA   Du X., Dutia M., Floyd M.B., Johnson M., Kenny C.H., Krishnamurthy G.,
RA   Moy F., Petusky S., Tkach D., Torres N., Wu B., Xu W.;
RT   "Lead identification to generate 3-cyanoquinoline inhibitors of insulin-
RT   like growth factor receptor (IGF-1R) for potential use in cancer
RT   treatment.";
RL   Bioorg. Med. Chem. Lett. 19:62-66(2009).
RN   [53]
RP   X-RAY CRYSTALLOGRAPHY (2.08 ANGSTROMS) OF 982-1286 IN COMPLEX WITH
RP   BMS-754807, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=19778024; DOI=10.1021/jm900786r;
RA   Wittman M.D., Carboni J.M., Yang Z., Lee F.Y., Antman M., Attar R.,
RA   Balimane P., Chang C., Chen C., Discenza L., Frennesson D., Gottardis M.M.,
RA   Greer A., Hurlburt W., Johnson W., Langley D.R., Li A., Li J., Liu P.,
RA   Mastalerz H., Mathur A., Menard K., Patel K., Sack J., Sang X.,
RA   Saulnier M., Smith D., Stefanski K., Trainor G., Velaparthi U., Zhang G.,
RA   Zimmermann K., Vyas D.M.;
RT   "Discovery of a 2,4-disubstituted pyrrolo[1,2-f][1,2,4]triazine inhibitor
RT   (BMS-754807) of insulin-like growth factor receptor (IGF-1R) kinase in
RT   clinical development.";
RL   J. Med. Chem. 52:7360-7363(2009).
RN   [54]
RP   X-RAY CRYSTALLOGRAPHY (1.79 ANGSTROMS) OF 983-1286 IN COMPLEX WITH
RP   MSC1609119A-1, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   DOI=10.1021/ml100044h;
RA   Heinrich T., Graedler U., Boettcher H., Blaukat A., Shutes A.;
RT   "Allosteric IGF-1R Inhibitors.";
RL   ACS Med. Chem. Lett. 1:199-203(2010).
RN   [55]
RP   X-RAY CRYSTALLOGRAPHY (2.11 ANGSTROMS) OF 982-1286 IN COMPLEXES WITH
RP   INHIBITORS, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=20675137; DOI=10.1016/j.bmcl.2010.07.045;
RA   Sampognaro A.J., Wittman M.D., Carboni J.M., Chang C., Greer A.F.,
RA   Hurlburt W.W., Sack J.S., Vyas D.M.;
RT   "Proline isosteres in a series of 2,4-disubstituted pyrrolo[1,2-
RT   f][1,2,4]triazine inhibitors of IGF-1R kinase and IR kinase.";
RL   Bioorg. Med. Chem. Lett. 20:5027-5030(2010).
RN   [56]
RP   X-RAY CRYSTALLOGRAPHY (3.00 ANGSTROMS) OF 951-1286 IN COMPLEX WITH
RP   BIS-AZAINDOLE INHIBITOR, AUTOPHOSPHORYLATION, AND ACTIVITY REGULATION.
RX   PubMed=20545947; DOI=10.1111/j.1747-0285.2010.00991.x;
RA   Nemecek C., Metz W.A., Wentzler S., Ding F.X., Venot C., Souaille C.,
RA   Dagallier A., Maignan S., Guilloteau J.P., Bernard F., Henry A.,
RA   Grapinet S., Lesuisse D.;
RT   "Design of potent IGF1-R inhibitors related to bis-azaindoles.";
RL   Chem. Biol. Drug Des. 76:100-106(2010).
RN   [57]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) OF 982-1286 IN COMPLEX WITH
RP   HYDANTOIN DERIVATIVE, CATALYTIC ACTIVITY, AND ACTIVITY REGULATION.
RX   PubMed=21441024; DOI=10.1016/j.bmcl.2011.03.003;
RA   Lesuisse D., Mauger J., Nemecek C., Maignan S., Boiziau J., Harlow G.,
RA   Hittinger A., Ruf S., Strobel H., Nair A., Ritter K., Malleron J.L.,
RA   Dagallier A., El-Ahmad Y., Guilloteau J.P., Guizani H., Bouchard H.,
RA   Venot C.;
RT   "Discovery of the first non-ATP competitive IGF-1R kinase inhibitors:
RT   advantages in comparison with competitive inhibitors.";
RL   Bioorg. Med. Chem. Lett. 21:2224-2228(2011).
RN   [58]
RP   X-RAY CRYSTALLOGRAPHY (2.90 ANGSTROMS) OF 988-1286 IN COMPLEX WITH
RP   2,4-BIS-ARYLAMINO-1,3-PYRIMIDINE INHIBITOR, CATALYTIC ACTIVITY, AND
RP   ACTIVITY REGULATION.
RX   PubMed=21414779; DOI=10.1016/j.bmcl.2011.02.075;
RA   Buchanan J.L., Newcomb J.R., Carney D.P., Chaffee S.C., Chai L.,
RA   Cupples R., Epstein L.F., Gallant P., Gu Y., Harmange J.C., Hodge K.,
RA   Houk B.E., Huang X., Jona J., Joseph S., Jun H.T., Kumar R., Li C., Lu J.,
RA   Menges T., Morrison M.J., Novak P.M., van der Plas S., Radinsky R.,
RA   Rose P.E., Sawant S., Sun J.R., Surapaneni S., Turci S.M., Xu K., Yanez E.,
RA   Zhao H., Zhu X.;
RT   "Discovery of 2,4-bis-arylamino-1,3-pyrimidines as insulin-like growth
RT   factor-1 receptor (IGF-1R) inhibitors.";
RL   Bioorg. Med. Chem. Lett. 21:2394-2399(2011).
RN   [59]
RP   VARIANTS IGF1RES GLN-138 AND ASN-145, AND CHARACTERIZATION OF VARIANTS
RP   IGF1RES GLN-138 AND ASN-145.
RX   PubMed=14657428; DOI=10.1056/nejmoa010107;
RG   The intrauterine growth retardation (IUGR) study group;
RA   Abuzzahab M.J., Schneider A., Goddard A., Grigorescu F., Lautier C.,
RA   Keller E., Kiess W., Klammt J., Kratzsch J., Osgood D., Pfaeffle R.,
RA   Raile K., Seidel B., Smith R.J., Chernausek S.D.;
RT   "IGF-I receptor mutations resulting in intrauterine and postnatal growth
RT   retardation.";
RL   N. Engl. J. Med. 349:2211-2222(2003).
RN   [60]
RP   VARIANT IGF1RES GLN-739, AND CHARACTERIZATION OF VARIANT IGF1RES GLN-739.
RX   PubMed=15928254; DOI=10.1210/jc.2004-1947;
RA   Kawashima Y., Kanzaki S., Yang F., Kinoshita T., Hanaki K., Nagaishi J.,
RA   Ohtsuka Y., Hisatome I., Ninomoya H., Nanba E., Fukushima T., Takahashi S.;
RT   "Mutation at cleavage site of insulin-like growth factor receptor in a
RT   short-stature child born with intrauterine growth retardation.";
RL   J. Clin. Endocrinol. Metab. 90:4679-4687(2005).
RN   [61]
RP   VARIANTS [LARGE SCALE ANALYSIS] LEU-105; HIS-437; HIS-595; SER-857;
RP   THR-1338 AND VAL-1347.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C., Bignell G.,
RA   Davies H., Teague J., Butler A., Stevens C., Edkins S., O'Meara S.,
RA   Vastrik I., Schmidt E.E., Avis T., Barthorpe S., Bhamra G., Buck G.,
RA   Choudhury B., Clements J., Cole J., Dicks E., Forbes S., Gray K.,
RA   Halliday K., Harrison R., Hills K., Hinton J., Jenkinson A., Jones D.,
RA   Menzies A., Mironenko T., Perry J., Raine K., Richardson D., Shepherd R.,
RA   Small A., Tofts C., Varian J., Webb T., West S., Widaa S., Yates A.,
RA   Cahill D.P., Louis D.N., Goldstraw P., Nicholson A.G., Brasseur F.,
RA   Looijenga L., Weber B.L., Chiew Y.-E., DeFazio A., Greaves M.F.,
RA   Green A.R., Campbell P., Birney E., Easton D.F., Chenevix-Trench G.,
RA   Tan M.-H., Khoo S.K., Teh B.T., Yuen S.T., Leung S.Y., Wooster R.,
RA   Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [62]
RP   VARIANTS IGF1RES TYR-359; CYS-865; SER-1256 AND CYS-1337, AND
RP   CHARACTERIZATION OF VARIANTS IGF1RES TYR-359; CYS-865; SER-1256 AND
RP   CYS-1337.
RX   PubMed=25040157; DOI=10.1111/cen.12555;
RA   Juanes M., Guercio G., Marino R., Berensztein E., Warman D.M., Ciaccio M.,
RA   Gil S., Bailez M., Rivarola M.A., Belgorosky A.;
RT   "Three novel IGF1R mutations in microcephalic patients with prenatal and
RT   postnatal growth impairment.";
RL   Clin. Endocrinol. (Oxf.) 82:704-711(2015).
CC   -!- FUNCTION: Receptor tyrosine kinase which mediates actions of insulin-
CC       like growth factor 1 (IGF1). Binds IGF1 with high affinity and IGF2 and
CC       insulin (INS) with a lower affinity. The activated IGF1R is involved in
CC       cell growth and survival control. IGF1R is crucial for tumor
CC       transformation and survival of malignant cell. Ligand binding activates
CC       the receptor kinase, leading to receptor autophosphorylation, and
CC       tyrosines phosphorylation of multiple substrates, that function as
CC       signaling adapter proteins including, the insulin-receptor substrates
CC       (IRS1/2), Shc and 14-3-3 proteins. Phosphorylation of IRSs proteins
CC       lead to the activation of two main signaling pathways: the PI3K-AKT/PKB
CC       pathway and the Ras-MAPK pathway. The result of activating the MAPK
CC       pathway is increased cellular proliferation, whereas activating the
CC       PI3K pathway inhibits apoptosis and stimulates protein synthesis.
CC       Phosphorylated IRS1 can activate the 85 kDa regulatory subunit of PI3K
CC       (PIK3R1), leading to activation of several downstream substrates,
CC       including protein AKT/PKB. AKT phosphorylation, in turn, enhances
CC       protein synthesis through mTOR activation and triggers the
CC       antiapoptotic effects of IGFIR through phosphorylation and inactivation
CC       of BAD. In parallel to PI3K-driven signaling, recruitment of Grb2/SOS
CC       by phosphorylated IRS1 or Shc leads to recruitment of Ras and
CC       activation of the ras-MAPK pathway. In addition to these two main
CC       signaling pathways IGF1R signals also through the Janus kinase/signal
CC       transducer and activator of transcription pathway (JAK/STAT).
CC       Phosphorylation of JAK proteins can lead to phosphorylation/activation
CC       of signal transducers and activators of transcription (STAT) proteins.
CC       In particular activation of STAT3, may be essential for the
CC       transforming activity of IGF1R. The JAK/STAT pathway activates gene
CC       transcription and may be responsible for the transforming activity. JNK
CC       kinases can also be activated by the IGF1R. IGF1 exerts inhibiting
CC       activities on JNK activation via phosphorylation and inhibition of
CC       MAP3K5/ASK1, which is able to directly associate with the IGF1R.
CC   -!- FUNCTION: When present in a hybrid receptor with INSR, binds IGF1.
CC       PubMed:12138094 shows that hybrid receptors composed of IGF1R and INSR
CC       isoform Long are activated with a high affinity by IGF1, with low
CC       affinity by IGF2 and not significantly activated by insulin, and that
CC       hybrid receptors composed of IGF1R and INSR isoform Short are activated
CC       by IGF1, IGF2 and insulin. In contrast, PubMed:16831875 shows that
CC       hybrid receptors composed of IGF1R and INSR isoform Long and hybrid
CC       receptors composed of IGF1R and INSR isoform Short have similar binding
CC       characteristics, both bind IGF1 and have a low affinity for insulin.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-tyrosyl-[protein] = ADP + H(+) + O-phospho-L-tyrosyl-
CC         [protein]; Xref=Rhea:RHEA:10596, Rhea:RHEA-COMP:10136, Rhea:RHEA-
CC         COMP:10137, ChEBI:CHEBI:15378, ChEBI:CHEBI:30616, ChEBI:CHEBI:46858,
CC         ChEBI:CHEBI:82620, ChEBI:CHEBI:456216; EC=2.7.10.1;
CC         Evidence={ECO:0000255|PROSITE-ProRule:PRU10028,
CC         ECO:0000269|PubMed:11694888, ECO:0000269|PubMed:17317169,
CC         ECO:0000269|PubMed:18566589, ECO:0000269|PubMed:19041240,
CC         ECO:0000269|PubMed:19778024, ECO:0000269|PubMed:20675137,
CC         ECO:0000269|PubMed:21414779, ECO:0000269|PubMed:21441024,
CC         ECO:0000269|PubMed:7679099, ECO:0000269|Ref.54};
CC   -!- ACTIVITY REGULATION: Activated by autophosphorylation at Tyr-1165, Tyr-
CC       1161 and Tyr-1166 on the kinase activation loop; phosphorylation at all
CC       three tyrosine residues is required for optimal kinase activity.
CC       Inhibited by MSC1609119A-1, BMS-754807, PQIP, benzimidazole pyridinone,
CC       isoquinolinedione, bis-azaindole, 3-cyanoquinoline, 2,4-bis-arylamino-
CC       1,3-pyrimidine, pyrrolopyrimidine, pyrrole-5-carboxaldehyde,
CC       picropodophyllin (PPP), tyrphostin derivatives. While most inhibitors
CC       bind to the ATP binding pocket, MSC1609119A-1 functions as allosteric
CC       inhibitor and binds close to the DFG motif and the activation loop.
CC       {ECO:0000269|PubMed:11694888, ECO:0000269|PubMed:14729630,
CC       ECO:0000269|PubMed:17317169, ECO:0000269|PubMed:18566589,
CC       ECO:0000269|PubMed:19041240, ECO:0000269|PubMed:19778024,
CC       ECO:0000269|PubMed:20545947, ECO:0000269|PubMed:20675137,
CC       ECO:0000269|PubMed:21414779, ECO:0000269|PubMed:21441024,
CC       ECO:0000269|Ref.54}.
CC   -!- SUBUNIT: Tetramer of 2 alpha and 2 beta chains linked by disulfide
CC       bonds. The alpha chains contribute to the formation of the ligand-
CC       binding domain, while the beta chain carries the kinase domain.
CC       Interacts with PIK3R1 and with the PTB/PID domains of IRS1 and SHC1 in
CC       vitro when autophosphorylated on tyrosine residues. Forms a hybrid
CC       receptor with INSR, the hybrid is a tetramer consisting of 1 alpha
CC       chain and 1 beta chain of INSR and 1 alpha chain and 1 beta chain of
CC       IGF1R. Interacts with ARRB1 and ARRB2. Interacts with GRB10. Interacts
CC       with RACK1. Interacts with SOCS1, SOCS2 and SOCS3. Interacts with 14-3-
CC       3 proteins. Interacts with NMD2. Interacts with MAP3K5. Interacts with
CC       STAT3. Found in a ternary complex with IGF1 and ITGAV:ITGB3 or
CC       ITGA6:ITGB4 (PubMed:19578119, PubMed:22351760). Interacts (nascent
CC       precursor form) with ZFAND2B (PubMed:26692333).
CC       {ECO:0000269|PubMed:10454568, ECO:0000269|PubMed:11071852,
CC       ECO:0000269|PubMed:11591350, ECO:0000269|PubMed:11694888,
CC       ECO:0000269|PubMed:11884618, ECO:0000269|PubMed:12556535,
CC       ECO:0000269|PubMed:12821780, ECO:0000269|PubMed:15878855,
CC       ECO:0000269|PubMed:15998644, ECO:0000269|PubMed:17317169,
CC       ECO:0000269|PubMed:1846292, ECO:0000269|PubMed:18566589,
CC       ECO:0000269|PubMed:19041240, ECO:0000269|PubMed:19578119,
CC       ECO:0000269|PubMed:19778024, ECO:0000269|PubMed:20545947,
CC       ECO:0000269|PubMed:21414779, ECO:0000269|PubMed:21441024,
CC       ECO:0000269|PubMed:22351760, ECO:0000269|PubMed:26692333,
CC       ECO:0000269|PubMed:7541045, ECO:0000269|PubMed:9581554,
CC       ECO:0000269|PubMed:9727029, ECO:0000269|PubMed:9822622,
CC       ECO:0000269|Ref.54}.
CC   -!- SUBUNIT: (Microbial infection) Interacts with human respiratory
CC       syncytial virus (HRSV) fusion glycoprotein F1/F2 heterodimer.
CC       {ECO:0000269|PubMed:32494007}.
CC   -!- INTERACTION:
CC       P08069; Q9NZN5: ARHGEF12; NbExp=7; IntAct=EBI-475981, EBI-821440;
CC       P08069; PRO_0000004724 [P49913]: CAMP; NbExp=3; IntAct=EBI-475981, EBI-6378485;
CC       P08069; P41240: CSK; NbExp=5; IntAct=EBI-475981, EBI-1380630;
CC       P08069; P35222: CTNNB1; NbExp=3; IntAct=EBI-475981, EBI-491549;
CC       P08069; P05019: IGF1; NbExp=8; IntAct=EBI-475981, EBI-7902275;
CC       P08069; P08069: IGF1R; NbExp=6; IntAct=EBI-475981, EBI-475981;
CC       P08069; P06213: INSR; NbExp=4; IntAct=EBI-475981, EBI-475899;
CC       P08069; P05556: ITGB1; NbExp=2; IntAct=EBI-475981, EBI-703066;
CC       P08069; Q9Y2W7: KCNIP3; NbExp=6; IntAct=EBI-475981, EBI-751501;
CC       P08069; Q9UJU2: LEF1; NbExp=5; IntAct=EBI-475981, EBI-926131;
CC       P08069; P27986: PIK3R1; NbExp=6; IntAct=EBI-475981, EBI-79464;
CC       P08069; O00459: PIK3R2; NbExp=3; IntAct=EBI-475981, EBI-346930;
CC       P08069; P35813: PPM1A; NbExp=2; IntAct=EBI-475981, EBI-989143;
CC       P08069; P18031: PTPN1; NbExp=4; IntAct=EBI-475981, EBI-968788;
CC       P08069; Q06124: PTPN11; NbExp=5; IntAct=EBI-475981, EBI-297779;
CC       P08069; P29350: PTPN6; NbExp=3; IntAct=EBI-475981, EBI-78260;
CC       P08069; P29353-2: SHC1; NbExp=2; IntAct=EBI-475981, EBI-1000553;
CC       P08069; Q01995: TAGLN; NbExp=2; IntAct=EBI-475981, EBI-1054248;
CC       P08069; Q64010: Crk; Xeno; NbExp=3; IntAct=EBI-475981, EBI-2906540;
CC       P08069; P01317: INS; Xeno; NbExp=4; IntAct=EBI-475981, EBI-3989070;
CC   -!- SUBCELLULAR LOCATION: Cell membrane {ECO:0000269|PubMed:17524361};
CC       Single-pass type I membrane protein {ECO:0000269|PubMed:17524361}.
CC   -!- TISSUE SPECIFICITY: Found as a hybrid receptor with INSR in muscle,
CC       heart, kidney, adipose tissue, skeletal muscle, hepatoma, fibroblasts,
CC       spleen and placenta (at protein level). Expressed in a variety of
CC       tissues. Overexpressed in tumors, including melanomas, cancers of the
CC       colon, pancreas prostate and kidney. {ECO:0000269|PubMed:12019176,
CC       ECO:0000269|PubMed:8247543, ECO:0000269|PubMed:9202395,
CC       ECO:0000269|PubMed:9355755}.
CC   -!- PTM: Autophosphorylated on tyrosine residues in response to ligand
CC       binding. Autophosphorylation occurs in trans, i.e. one subunit of the
CC       dimeric receptor phosphorylates tyrosine residues on the other subunit.
CC       Autophosphorylation occurs in a sequential manner; Tyr-1165 is
CC       predominantly phosphorylated first, followed by phosphorylation of Tyr-
CC       1161 and Tyr-1166. While every single phosphorylation increases kinase
CC       activity, all three tyrosine residues in the kinase activation loop
CC       (Tyr-1165, Tyr-1161 and Tyr-1166) have to be phosphorylated for optimal
CC       activity. Can be autophosphorylated at additional tyrosine residues (in
CC       vitro). Autophosphorylated is followed by phosphorylation of
CC       juxtamembrane tyrosines and C-terminal serines. Phosphorylation of Tyr-
CC       980 is required for IRS1- and SHC1-binding. Phosphorylation of Ser-1278
CC       by GSK-3beta restrains kinase activity and promotes cell surface
CC       expression, it requires a priming phosphorylation at Ser-1282.
CC       Dephosphorylated by PTPN1 (By similarity). {ECO:0000250}.
CC   -!- PTM: Polyubiquitinated at Lys-1168 and Lys-1171 through both 'Lys-48'
CC       and 'Lys-29' linkages, promoting receptor endocytosis and subsequent
CC       degradation by the proteasome. Ubiquitination is facilitated by pre-
CC       existing phosphorylation. {ECO:0000269|PubMed:11694888,
CC       ECO:0000269|PubMed:12821780, ECO:0000269|PubMed:18501599,
CC       ECO:0000269|PubMed:19041240, ECO:0000269|PubMed:21994939,
CC       ECO:0000269|PubMed:7541045}.
CC   -!- PTM: Sumoylated with SUMO1. {ECO:0000269|PubMed:20596523}.
CC   -!- PTM: Controlled by regulated intramembrane proteolysis (RIP). Undergoes
CC       metalloprotease-dependent constitutive ectodomain shedding to produce a
CC       membrane-anchored 52 kDa C-Terminal fragment which is further processed
CC       by presenilin gamma-secretase to yield an intracellular 50 kDa
CC       fragment. {ECO:0000269|PubMed:17524361}.
CC   -!- DISEASE: Insulin-like growth factor 1 resistance (IGF1RES)
CC       [MIM:270450]: A disorder characterized by intrauterine growth
CC       retardation, poor postnatal growth and increased plasma IGF1 levels.
CC       {ECO:0000269|PubMed:14657428, ECO:0000269|PubMed:15928254,
CC       ECO:0000269|PubMed:25040157}. Note=The disease is caused by variants
CC       affecting the gene represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. Tyr protein
CC       kinase family. Insulin receptor subfamily. {ECO:0000255|PROSITE-
CC       ProRule:PRU00159}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAG11657.1; Type=Erroneous initiation; Note=Extended N-terminus.; Evidence={ECO:0000305};
CC   -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and
CC       Haematology;
CC       URL="http://atlasgeneticsoncology.org/Genes/IGF1RID40928ch15q26.html";
CC   -!- WEB RESOURCE: Name=NIEHS-SNPs;
CC       URL="http://egp.gs.washington.edu/data/igf1r/";
CC   -!- WEB RESOURCE: Name=Wikipedia; Note=IGF-1 receptor entry;
CC       URL="https://en.wikipedia.org/wiki/IGF-1_receptor";
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; X04434; CAA28030.1; -; mRNA.
DR   EMBL; AB425196; BAG11657.1; ALT_INIT; mRNA.
DR   EMBL; AY332722; AAP81165.1; -; Genomic_DNA.
DR   EMBL; AC055807; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC069029; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC118658; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC118660; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC113610; AAI13611.1; -; mRNA.
DR   EMBL; BC113612; AAI13613.1; -; mRNA.
DR   EMBL; M69229; AAB59399.1; -; Genomic_DNA.
DR   CCDS; CCDS10378.1; -.
DR   PIR; A25690; IGHUR1.
DR   RefSeq; NP_000866.1; NM_000875.4.
DR   RefSeq; NP_001278787.1; NM_001291858.1.
DR   PDB; 1IGR; X-ray; 2.60 A; A=31-492.
DR   PDB; 1JQH; X-ray; 2.10 A; A/B/C=979-1286.
DR   PDB; 1K3A; X-ray; 2.10 A; A=988-1286.
DR   PDB; 1M7N; X-ray; 2.70 A; A/B=974-1294.
DR   PDB; 1P4O; X-ray; 1.50 A; A/B=974-1294.
DR   PDB; 2OJ9; X-ray; 2.00 A; A=982-1286.
DR   PDB; 2ZM3; X-ray; 2.50 A; A/B/C/D=981-1286.
DR   PDB; 3D94; X-ray; 2.30 A; A=986-1286.
DR   PDB; 3F5P; X-ray; 2.90 A; A/B/C/D/E/F/G/H/I/J/K/L/M/R/S/T=981-1286.
DR   PDB; 3I81; X-ray; 2.08 A; A=982-1286.
DR   PDB; 3LVP; X-ray; 3.00 A; A/B/C/D=951-1286.
DR   PDB; 3LW0; X-ray; 1.79 A; A/B/C/D=983-1286.
DR   PDB; 3NW5; X-ray; 2.14 A; A=982-1286.
DR   PDB; 3NW6; X-ray; 2.20 A; A=982-1286.
DR   PDB; 3NW7; X-ray; 2.11 A; A=982-1286.
DR   PDB; 3O23; X-ray; 2.10 A; A=982-1286.
DR   PDB; 3QQU; X-ray; 2.90 A; A/B/C/D=988-1286.
DR   PDB; 4D2R; X-ray; 2.10 A; A=985-1286.
DR   PDB; 4XSS; X-ray; 3.00 A; F=721-736.
DR   PDB; 5FXQ; X-ray; 2.30 A; A=980-1286.
DR   PDB; 5FXR; X-ray; 2.40 A; A=980-1286.
DR   PDB; 5FXS; X-ray; 1.90 A; A=980-1286.
DR   PDB; 5HZN; X-ray; 2.20 A; A/B/C/D/E/F/G/H=983-1286.
DR   PDB; 5U8Q; X-ray; 3.27 A; A=31-935.
DR   PDB; 5U8R; X-ray; 3.00 A; A=31-935.
DR   PDB; 6JK8; EM; 4.70 A; A/B=1-1367.
DR   PDB; 6VWG; EM; 3.21 A; A/B=31-935.
DR   PDB; 6VWH; EM; 4.26 A; A/B=31-935.
DR   PDB; 6VWI; EM; 3.70 A; A/B=31-935.
DR   PDB; 6VWJ; EM; 4.21 A; A/B=31-935.
DR   PDBsum; 1IGR; -.
DR   PDBsum; 1JQH; -.
DR   PDBsum; 1K3A; -.
DR   PDBsum; 1M7N; -.
DR   PDBsum; 1P4O; -.
DR   PDBsum; 2OJ9; -.
DR   PDBsum; 2ZM3; -.
DR   PDBsum; 3D94; -.
DR   PDBsum; 3F5P; -.
DR   PDBsum; 3I81; -.
DR   PDBsum; 3LVP; -.
DR   PDBsum; 3LW0; -.
DR   PDBsum; 3NW5; -.
DR   PDBsum; 3NW6; -.
DR   PDBsum; 3NW7; -.
DR   PDBsum; 3O23; -.
DR   PDBsum; 3QQU; -.
DR   PDBsum; 4D2R; -.
DR   PDBsum; 4XSS; -.
DR   PDBsum; 5FXQ; -.
DR   PDBsum; 5FXR; -.
DR   PDBsum; 5FXS; -.
DR   PDBsum; 5HZN; -.
DR   PDBsum; 5U8Q; -.
DR   PDBsum; 5U8R; -.
DR   PDBsum; 6JK8; -.
DR   PDBsum; 6VWG; -.
DR   PDBsum; 6VWH; -.
DR   PDBsum; 6VWI; -.
DR   PDBsum; 6VWJ; -.
DR   AlphaFoldDB; P08069; -.
DR   SASBDB; P08069; -.
DR   SMR; P08069; -.
DR   BioGRID; 109701; 272.
DR   CORUM; P08069; -.
DR   DIP; DIP-476N; -.
DR   IntAct; P08069; 346.
DR   MINT; P08069; -.
DR   STRING; 9606.ENSP00000268035; -.
DR   BindingDB; P08069; -.
DR   ChEMBL; CHEMBL1957; -.
DR   DrugBank; DB07156; (4Z)-6-bromo-4-({[4-(pyrrolidin-1-ylmethyl)phenyl]amino}methylidene)isoquinoline-1,3(2H,4H)-dione.
DR   DrugBank; DB07474; 3-[5-(1H-IMIDAZOL-1-YL)-7-METHYL-1H-BENZIMIDAZOL-2-YL]-4-[(PYRIDIN-2-YLMETHYL)AMINO]PYRIDIN-2(1H)-ONE.
DR   DrugBank; DB05023; ATL1101.
DR   DrugBank; DB15399; BMS-754807.
DR   DrugBank; DB12267; Brigatinib.
DR   DrugBank; DB12250; Cixutumumab.
DR   DrugBank; DB11564; Insulin argine.
DR   DrugBank; DB01306; Insulin aspart.
DR   DrugBank; DB09456; Insulin beef.
DR   DrugBank; DB09564; Insulin degludec.
DR   DrugBank; DB01307; Insulin detemir.
DR   DrugBank; DB00047; Insulin glargine.
DR   DrugBank; DB01309; Insulin glulisine.
DR   DrugBank; DB00030; Insulin human.
DR   DrugBank; DB00046; Insulin lispro.
DR   DrugBank; DB11567; Insulin peglispro.
DR   DrugBank; DB00071; Insulin pork.
DR   DrugBank; DB11568; Insulin tregopil.
DR   DrugBank; DB16637; KW-2450 free base.
DR   DrugBank; DB06075; Linsitinib.
DR   DrugBank; DB01277; Mecasermin.
DR   DrugBank; DB14751; Mecasermin rinfabate.
DR   DrugBank; DB08804; Nandrolone decanoate.
DR   DrugBank; DB04395; Phosphoaminophosphonic Acid-Adenylate Ester.
DR   DrugBank; DB05897; rhIGFBP-3.
DR   DrugBank; DB09098; Somatrem.
DR   DrugBank; DB06343; Teprotumumab.
DR   DrugBank; DB05184; XL228.
DR   DrugCentral; P08069; -.
DR   GuidetoPHARMACOLOGY; 1801; -.
DR   GlyGen; P08069; 18 sites, 1 Thr glycan (1 site).
DR   iPTMnet; P08069; -.
DR   PhosphoSitePlus; P08069; -.
DR   BioMuta; IGF1R; -.
DR   DMDM; 124240; -.
DR   EPD; P08069; -.
DR   jPOST; P08069; -.
DR   MassIVE; P08069; -.
DR   MaxQB; P08069; -.
DR   PaxDb; P08069; -.
DR   PeptideAtlas; P08069; -.
DR   PRIDE; P08069; -.
DR   ProteomicsDB; 52065; -.
DR   ABCD; P08069; 27 sequenced antibodies.
DR   Antibodypedia; 4140; 2573 antibodies from 48 providers.
DR   DNASU; 3480; -.
DR   Ensembl; ENST00000650285.1; ENSP00000497069.1; ENSG00000140443.15.
DR   GeneID; 3480; -.
DR   KEGG; hsa:3480; -.
DR   MANE-Select; ENST00000650285.1; ENSP00000497069.1; NM_000875.5; NP_000866.1.
DR   UCSC; uc002bul.4; human.
DR   CTD; 3480; -.
DR   DisGeNET; 3480; -.
DR   GeneCards; IGF1R; -.
DR   HGNC; HGNC:5465; IGF1R.
DR   HPA; ENSG00000140443; Low tissue specificity.
DR   MalaCards; IGF1R; -.
DR   MIM; 147370; gene.
DR   MIM; 270450; phenotype.
DR   neXtProt; NX_P08069; -.
DR   OpenTargets; ENSG00000140443; -.
DR   Orphanet; 73273; Growth delay due to insulin-like growth factor I resistance.
DR   PharmGKB; PA29698; -.
DR   VEuPathDB; HostDB:ENSG00000140443; -.
DR   eggNOG; KOG4258; Eukaryota.
DR   GeneTree; ENSGT00940000156682; -.
DR   InParanoid; P08069; -.
DR   OMA; KFRGYAF; -.
DR   OrthoDB; 223327at2759; -.
DR   PhylomeDB; P08069; -.
DR   TreeFam; TF351636; -.
DR   BRENDA; 2.7.10.1; 2681.
DR   PathwayCommons; P08069; -.
DR   Reactome; R-HSA-2404192; Signaling by Type 1 Insulin-like Growth Factor 1 Receptor (IGF1R).
DR   Reactome; R-HSA-2428928; IRS-related events triggered by IGF1R.
DR   Reactome; R-HSA-2428933; SHC-related events triggered by IGF1R.
DR   Reactome; R-HSA-9009391; Extra-nuclear estrogen signaling.
DR   SignaLink; P08069; -.
DR   SIGNOR; P08069; -.
DR   BioGRID-ORCS; 3480; 189 hits in 1122 CRISPR screens.
DR   ChiTaRS; IGF1R; human.
DR   EvolutionaryTrace; P08069; -.
DR   GeneWiki; Insulin-like_growth_factor_1_receptor; -.
DR   GenomeRNAi; 3480; -.
DR   Pharos; P08069; Tclin.
DR   PRO; PR:P08069; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; P08069; protein.
DR   Bgee; ENSG00000140443; Expressed in caput epididymis and 206 other tissues.
DR   ExpressionAtlas; P08069; baseline and differential.
DR   Genevisible; P08069; HS.
DR   GO; GO:0035867; C:alphav-beta3 integrin-IGF-1-IGF1R complex; IDA:UniProtKB.
DR   GO; GO:0030424; C:axon; IBA:GO_Central.
DR   GO; GO:0005901; C:caveola; IEA:Ensembl.
DR   GO; GO:0005737; C:cytoplasm; IEA:Ensembl.
DR   GO; GO:0005899; C:insulin receptor complex; IBA:GO_Central.
DR   GO; GO:0005887; C:integral component of plasma membrane; IBA:GO_Central.
DR   GO; GO:0043231; C:intracellular membrane-bounded organelle; IDA:BHF-UCL.
DR   GO; GO:0016020; C:membrane; IDA:BHF-UCL.
DR   GO; GO:0043025; C:neuronal cell body; IEA:Ensembl.
DR   GO; GO:0005634; C:nucleus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; ISS:AgBase.
DR   GO; GO:1902911; C:protein kinase complex; IDA:UniProtKB.
DR   GO; GO:0043235; C:receptor complex; IDA:MGI.
DR   GO; GO:0030315; C:T-tubule; IEA:Ensembl.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0001965; F:G-protein alpha-subunit binding; IEA:Ensembl.
DR   GO; GO:0042802; F:identical protein binding; IPI:IntAct.
DR   GO; GO:0043559; F:insulin binding; IPI:BHF-UCL.
DR   GO; GO:0005009; F:insulin receptor activity; IBA:GO_Central.
DR   GO; GO:0005158; F:insulin receptor binding; IDA:BHF-UCL.
DR   GO; GO:0043560; F:insulin receptor substrate binding; IPI:UniProtKB.
DR   GO; GO:0005520; F:insulin-like growth factor binding; IDA:UniProtKB.
DR   GO; GO:0031994; F:insulin-like growth factor I binding; IDA:UniProtKB.
DR   GO; GO:0005010; F:insulin-like growth factor receptor activity; IDA:UniProtKB.
DR   GO; GO:0043548; F:phosphatidylinositol 3-kinase binding; IPI:UniProtKB.
DR   GO; GO:0140318; F:protein transporter activity; IMP:ARUK-UCL.
DR   GO; GO:0004713; F:protein tyrosine kinase activity; IDA:UniProtKB.
DR   GO; GO:0005198; F:structural molecule activity; IDA:UniProtKB.
DR   GO; GO:0004714; F:transmembrane receptor protein tyrosine kinase activity; IBA:GO_Central.
DR   GO; GO:0007568; P:aging; IEA:Ensembl.
DR   GO; GO:0097242; P:amyloid-beta clearance; IMP:ARUK-UCL.
DR   GO; GO:0007409; P:axonogenesis; IEA:Ensembl.
DR   GO; GO:0003230; P:cardiac atrium development; IEA:Ensembl.
DR   GO; GO:1904045; P:cellular response to aldosterone; IEA:Ensembl.
DR   GO; GO:1904646; P:cellular response to amyloid-beta; IGI:ARUK-UCL.
DR   GO; GO:1904385; P:cellular response to angiotensin; IEA:Ensembl.
DR   GO; GO:0071549; P:cellular response to dexamethasone stimulus; IEA:Ensembl.
DR   GO; GO:0071392; P:cellular response to estradiol stimulus; IEA:Ensembl.
DR   GO; GO:0071333; P:cellular response to glucose stimulus; IBA:GO_Central.
DR   GO; GO:1990314; P:cellular response to insulin-like growth factor stimulus; IEA:Ensembl.
DR   GO; GO:0071260; P:cellular response to mechanical stimulus; IEA:Ensembl.
DR   GO; GO:0071393; P:cellular response to progesterone stimulus; IEA:Ensembl.
DR   GO; GO:0071394; P:cellular response to testosterone stimulus; IEA:Ensembl.
DR   GO; GO:0071560; P:cellular response to transforming growth factor beta stimulus; IEA:Ensembl.
DR   GO; GO:0034224; P:cellular response to zinc ion starvation; IEA:Ensembl.
DR   GO; GO:0090398; P:cellular senescence; IEA:Ensembl.
DR   GO; GO:0021549; P:cerebellum development; IEA:Ensembl.
DR   GO; GO:0097062; P:dendritic spine maintenance; ISS:ARUK-UCL.
DR   GO; GO:0030010; P:establishment of cell polarity; IEA:Ensembl.
DR   GO; GO:0044849; P:estrous cycle; IEA:Ensembl.
DR   GO; GO:0042593; P:glucose homeostasis; IBA:GO_Central.
DR   GO; GO:0021766; P:hippocampus development; IEA:Ensembl.
DR   GO; GO:0006955; P:immune response; IMP:BHF-UCL.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; ISS:ARUK-UCL.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; IDA:UniProtKB.
DR   GO; GO:0043066; P:negative regulation of apoptotic process; IDA:UniProtKB.
DR   GO; GO:1904193; P:negative regulation of cholangiocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:1903944; P:negative regulation of hepatocyte apoptotic process; IEA:Ensembl.
DR   GO; GO:0043409; P:negative regulation of MAPK cascade; IDA:GO_Central.
DR   GO; GO:0010656; P:negative regulation of muscle cell apoptotic process; IEA:Ensembl.
DR   GO; GO:0038083; P:peptidyl-tyrosine autophosphorylation; IMP:MGI.
DR   GO; GO:0014065; P:phosphatidylinositol 3-kinase signaling; IC:BHF-UCL.
DR   GO; GO:0048015; P:phosphatidylinositol-mediated signaling; IDA:BHF-UCL.
DR   GO; GO:0048680; P:positive regulation of axon regeneration; IEA:Ensembl.
DR   GO; GO:0030335; P:positive regulation of cell migration; IMP:BHF-UCL.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IMP:BHF-UCL.
DR   GO; GO:0120162; P:positive regulation of cold-induced thermogenesis; ISS:YuBioLab.
DR   GO; GO:0032467; P:positive regulation of cytokinesis; IEA:Ensembl.
DR   GO; GO:0051054; P:positive regulation of DNA metabolic process; IEA:Ensembl.
DR   GO; GO:0033674; P:positive regulation of kinase activity; IBA:GO_Central.
DR   GO; GO:0043410; P:positive regulation of MAPK cascade; IBA:GO_Central.
DR   GO; GO:0033690; P:positive regulation of osteoblast proliferation; IEA:Ensembl.
DR   GO; GO:0014068; P:positive regulation of phosphatidylinositol 3-kinase signaling; IBA:GO_Central.
DR   GO; GO:0051897; P:positive regulation of protein kinase B signaling; IBA:GO_Central.
DR   GO; GO:0043243; P:positive regulation of protein-containing complex disassembly; ISS:ARUK-UCL.
DR   GO; GO:0048661; P:positive regulation of smooth muscle cell proliferation; IEA:Ensembl.
DR   GO; GO:0090031; P:positive regulation of steroid hormone biosynthetic process; IEA:Ensembl.
DR   GO; GO:0046777; P:protein autophosphorylation; IDA:UniProtKB.
DR   GO; GO:0046328; P:regulation of JNK cascade; IDA:UniProtKB.
DR   GO; GO:0045471; P:response to ethanol; IEA:Ensembl.
DR   GO; GO:1902065; P:response to L-glutamate; IEA:Ensembl.
DR   GO; GO:0035094; P:response to nicotine; IEA:Ensembl.
DR   GO; GO:0033197; P:response to vitamin E; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   GO; GO:0045056; P:transcytosis; IMP:ARUK-UCL.
DR   GO; GO:0007169; P:transmembrane receptor protein tyrosine kinase signaling pathway; IBA:GO_Central.
DR   CDD; cd00063; FN3; 3.
DR   CDD; cd00064; FU; 1.
DR   Gene3D; 2.60.40.10; -; 3.
DR   Gene3D; 3.80.20.20; -; 2.
DR   InterPro; IPR003961; FN3_dom.
DR   InterPro; IPR036116; FN3_sf.
DR   InterPro; IPR006211; Furin-like_Cys-rich_dom.
DR   InterPro; IPR006212; Furin_repeat.
DR   InterPro; IPR009030; Growth_fac_rcpt_cys_sf.
DR   InterPro; IPR013783; Ig-like_fold.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR000494; Rcpt_L-dom.
DR   InterPro; IPR036941; Rcpt_L-dom_sf.
DR   InterPro; IPR001245; Ser-Thr/Tyr_kinase_cat_dom.
DR   InterPro; IPR008266; Tyr_kinase_AS.
DR   InterPro; IPR020635; Tyr_kinase_cat_dom.
DR   InterPro; IPR016246; Tyr_kinase_insulin-like_rcpt.
DR   InterPro; IPR002011; Tyr_kinase_rcpt_2_CS.
DR   Pfam; PF00757; Furin-like; 1.
DR   Pfam; PF07714; PK_Tyr_Ser-Thr; 1.
DR   Pfam; PF01030; Recep_L_domain; 2.
DR   PIRSF; PIRSF000620; Insulin_receptor; 1.
DR   PRINTS; PR00109; TYRKINASE.
DR   SMART; SM00060; FN3; 3.
DR   SMART; SM00261; FU; 1.
DR   SMART; SM00219; TyrKc; 1.
DR   SUPFAM; SSF49265; SSF49265; 3.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   SUPFAM; SSF57184; SSF57184; 1.
DR   PROSITE; PS50853; FN3; 4.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00109; PROTEIN_KINASE_TYR; 1.
DR   PROSITE; PS00239; RECEPTOR_TYR_KIN_II; 1.
PE   1: Evidence at protein level;
KW   3D-structure; ATP-binding; Cell membrane;
KW   Cleavage on pair of basic residues; Direct protein sequencing;
KW   Disease variant; Disulfide bond; Glycoprotein; Host-virus interaction;
KW   Isopeptide bond; Kinase; Membrane; Nucleotide-binding; Phosphoprotein;
KW   Receptor; Reference proteome; Repeat; Signal; Transferase; Transmembrane;
KW   Transmembrane helix; Tyrosine-protein kinase; Ubl conjugation.
FT   SIGNAL          1..30
FT                   /evidence="ECO:0000269|PubMed:2877871,
FT                   ECO:0000269|PubMed:8257688"
FT   CHAIN           31..736
FT                   /note="Insulin-like growth factor 1 receptor alpha chain"
FT                   /id="PRO_0000016681"
FT   CHAIN           741..1367
FT                   /note="Insulin-like growth factor 1 receptor beta chain"
FT                   /id="PRO_0000016682"
FT   TOPO_DOM        741..935
FT                   /note="Extracellular"
FT                   /evidence="ECO:0000255"
FT   TRANSMEM        936..959
FT                   /note="Helical"
FT                   /evidence="ECO:0000255"
FT   TOPO_DOM        960..1367
FT                   /note="Cytoplasmic"
FT                   /evidence="ECO:0000255"
FT   DOMAIN          491..609
FT                   /note="Fibronectin type-III 1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          610..708
FT                   /note="Fibronectin type-III 2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          735..828
FT                   /note="Fibronectin type-III 3"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          834..927
FT                   /note="Fibronectin type-III 4"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00316"
FT   DOMAIN          999..1274
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          1288..1367
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   MOTIF           977..980
FT                   /note="IRS1- and SHC1-binding"
FT   ACT_SITE        1135
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000255|PROSITE-ProRule:PRU10028"
FT   BINDING         1005..1013
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         1033
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT   MOD_RES         980
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0000305|PubMed:7541045"
FT   MOD_RES         1161
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11694888,
FT                   ECO:0000269|PubMed:18501599, ECO:0000269|PubMed:19041240"
FT   MOD_RES         1165
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11694888,
FT                   ECO:0000269|PubMed:18501599, ECO:0000269|PubMed:19041240"
FT   MOD_RES         1166
FT                   /note="Phosphotyrosine; by autocatalysis"
FT                   /evidence="ECO:0000269|PubMed:11694888,
FT                   ECO:0000269|PubMed:18501599, ECO:0000269|PubMed:19041240"
FT   MOD_RES         1278
FT                   /note="Phosphoserine; by GSK3-beta"
FT                   /evidence="ECO:0000250|UniProtKB:Q60751"
FT   MOD_RES         1282
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q60751"
FT   CARBOHYD        51
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   CARBOHYD        102
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        135
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   CARBOHYD        244
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   CARBOHYD        314
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   CARBOHYD        417
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        438
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        534
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        607
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        622
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        640
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        747
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        756
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        764
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        900
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   CARBOHYD        913
FT                   /note="N-linked (GlcNAc...) asparagine"
FT                   /evidence="ECO:0000255"
FT   DISULFID        33..52
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   DISULFID        150..178
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   DISULFID        182..205
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   DISULFID        192..211
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   DISULFID        215..224
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   DISULFID        219..230
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   DISULFID        231..239
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   DISULFID        235..248
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   DISULFID        251..260
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   DISULFID        264..276
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   DISULFID        282..303
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   DISULFID        307..321
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   DISULFID        324..328
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   DISULFID        332..353
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   DISULFID        455..488
FT                   /evidence="ECO:0000269|PubMed:9690478"
FT   CROSSLNK        1168
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:21994939"
FT   CROSSLNK        1171
FT                   /note="Glycyl lysine isopeptide (Lys-Gly) (interchain with
FT                   G-Cter in ubiquitin)"
FT                   /evidence="ECO:0000269|PubMed:21994939"
FT   VARIANT         105
FT                   /note="V -> L (in a renal chromophobe sample; somatic
FT                   mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041424"
FT   VARIANT         138
FT                   /note="R -> Q (in IGF1RES; has decreased IGF1R function;
FT                   dbSNP:rs121912426)"
FT                   /evidence="ECO:0000269|PubMed:14657428"
FT                   /id="VAR_034891"
FT   VARIANT         145
FT                   /note="K -> N (in IGF1RES; has decreased IGF1R function;
FT                   dbSNP:rs121912427)"
FT                   /evidence="ECO:0000269|PubMed:14657428"
FT                   /id="VAR_034892"
FT   VARIANT         359
FT                   /note="N -> Y (in IGF1RES; significant decrease in
FT                   IGF1-induced DNA synthesis and AKT1 phosphorylation in
FT                   patient fibroblasts)"
FT                   /evidence="ECO:0000269|PubMed:25040157"
FT                   /id="VAR_076247"
FT   VARIANT         388
FT                   /note="V -> M (in dbSNP:rs45445894)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_018855"
FT   VARIANT         437
FT                   /note="R -> H (in dbSNP:rs34516635)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_034893"
FT   VARIANT         511
FT                   /note="R -> Q (in dbSNP:rs33958176)"
FT                   /id="VAR_034894"
FT   VARIANT         595
FT                   /note="R -> H (in dbSNP:rs56248469)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041425"
FT   VARIANT         605
FT                   /note="R -> H (in dbSNP:rs45553041)"
FT                   /evidence="ECO:0000269|Ref.4"
FT                   /id="VAR_018856"
FT   VARIANT         739
FT                   /note="R -> Q (in IGF1RES; leads to failure of processing
FT                   of the IGF1R proreceptor to mature IGF1R;
FT                   dbSNP:rs121912429)"
FT                   /evidence="ECO:0000269|PubMed:15928254"
FT                   /id="VAR_034895"
FT   VARIANT         808
FT                   /note="H -> R (in dbSNP:rs34061581)"
FT                   /id="VAR_034896"
FT   VARIANT         828
FT                   /note="A -> T (in dbSNP:rs35224135)"
FT                   /id="VAR_034897"
FT   VARIANT         857
FT                   /note="N -> S (in dbSNP:rs45611935)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041426"
FT   VARIANT         865
FT                   /note="Y -> C (in IGF1RES; significant decrease in
FT                   IGF1-induced DNA synthesis and AKT1 phosphorylation in
FT                   patient fibroblasts)"
FT                   /evidence="ECO:0000269|PubMed:25040157"
FT                   /id="VAR_076248"
FT   VARIANT         1256
FT                   /note="R -> S (in IGF1RES; significant decrease in
FT                   IGF1-induced DNA synthesis and AKT1 phosphorylation in
FT                   patient fibroblasts)"
FT                   /evidence="ECO:0000269|PubMed:25040157"
FT                   /id="VAR_076249"
FT   VARIANT         1337
FT                   /note="R -> C (in IGF1RES; unknown pathological
FT                   significance; significant decrease in IGF1-induced DNA
FT                   synthesis; significant increase in IGF1-induced AKT1
FT                   phosphorylation in patient fibroblasts; dbSNP:rs141802822)"
FT                   /evidence="ECO:0000269|PubMed:25040157"
FT                   /id="VAR_076250"
FT   VARIANT         1338
FT                   /note="A -> T (in dbSNP:rs34102392)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041427"
FT   VARIANT         1347
FT                   /note="A -> V (in a lung squamous cell carcinoma sample;
FT                   somatic mutation)"
FT                   /evidence="ECO:0000269|PubMed:17344846"
FT                   /id="VAR_041428"
FT   MUTAGEN         980
FT                   /note="Y->F: Reduces tyrosine phosphorylation. Abolishes
FT                   interaction with IRS1 and SHC1. Does not abolish
FT                   interaction with PIK3R1, nor with GRB10."
FT                   /evidence="ECO:0000269|PubMed:10454568,
FT                   ECO:0000269|PubMed:7541045"
FT   MUTAGEN         1033
FT                   /note="K->A: Kinase inactive. Abolishes tyrosine
FT                   phosphorylation and abolishes interaction with IRS1, SHC1
FT                   and PIK3R1."
FT                   /evidence="ECO:0000269|PubMed:7541045"
FT   MUTAGEN         1280
FT                   /note="Y->F: No effect on GRB10-binding."
FT                   /evidence="ECO:0000269|PubMed:10454568"
FT   MUTAGEN         1281
FT                   /note="Y->F: No effect on GRB10-binding."
FT                   /evidence="ECO:0000269|PubMed:10454568"
FT   MUTAGEN         1346
FT                   /note="Y->F: Loss of GRB10-binding."
FT                   /evidence="ECO:0000269|PubMed:10454568"
FT   CONFLICT        928..929
FT                   /note="TG -> R (in Ref. 3; BAG11657)"
FT                   /evidence="ECO:0000305"
FT   STRAND          37..41
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   HELIX           43..49
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          53..57
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          59..65
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          68..70
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          80..83
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          85..92
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   HELIX           96..98
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          115..121
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          138..144
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          152..154
FT                   /evidence="ECO:0007829|PDB:6VWG"
FT   HELIX           157..160
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   HELIX           164..166
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          168..171
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   HELIX           175..178
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   TURN            183..188
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          194..199
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          201..203
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          205..209
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   HELIX           217..219
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          222..224
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   HELIX           226..228
FT                   /evidence="ECO:0007829|PDB:6VWG"
FT   STRAND          235..241
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          247..255
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          257..263
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          269..271
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   TURN            272..274
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          275..277
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   HELIX           279..283
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          297..299
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          302..306
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          311..315
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          321..323
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          325..327
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          331..341
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   HELIX           345..347
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   TURN            349..352
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          354..362
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   HELIX           375..378
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          383..386
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          388..392
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          397..399
FT                   /evidence="ECO:0007829|PDB:6VWG"
FT   TURN            415..417
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          418..423
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   TURN            434..436
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          440..443
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          445..451
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          452..454
FT                   /evidence="ECO:0007829|PDB:5U8Q"
FT   HELIX           456..466
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   TURN            469..471
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          474..477
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   TURN            479..481
FT                   /evidence="ECO:0007829|PDB:1IGR"
FT   STRAND          482..485
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          491..493
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          495..500
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          505..509
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   HELIX           517..519
FT                   /evidence="ECO:0007829|PDB:6VWG"
FT   STRAND          520..529
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          531..533
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   TURN            542..544
FT                   /evidence="ECO:0007829|PDB:5U8Q"
FT   STRAND          550..552
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          565..568
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          576..586
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          591..593
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          597..599
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          602..605
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          615..620
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          626..632
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          644..650
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          655..660
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   TURN            662..664
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   HELIX           724..730
FT                   /evidence="ECO:0007829|PDB:4XSS"
FT   STRAND          777..782
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          786..792
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          798..805
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   HELIX           810..813
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          821..824
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          839..843
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   TURN            844..846
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          847..851
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          862..873
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          876..881
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   HELIX           882..888
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          889..893
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          898..911
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          920..924
FT                   /evidence="ECO:0007829|PDB:5U8R"
FT   STRAND          980..982
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   HELIX           983..985
FT                   /evidence="ECO:0007829|PDB:2ZM3"
FT   TURN            990..992
FT                   /evidence="ECO:0007829|PDB:2OJ9"
FT   HELIX           996..998
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   STRAND          999..1007
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   STRAND          1009..1022
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   STRAND          1025..1034
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   STRAND          1037..1039
FT                   /evidence="ECO:0007829|PDB:3F5P"
FT   HELIX           1041..1053
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   HELIX           1054..1056
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   STRAND          1065..1069
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   STRAND          1071..1074
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   STRAND          1076..1080
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   HELIX           1087..1100
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   HELIX           1109..1128
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   HELIX           1138..1140
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   STRAND          1141..1143
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   STRAND          1149..1151
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   HELIX           1155..1157
FT                   /evidence="ECO:0007829|PDB:3D94"
FT   HELIX           1159..1164
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   TURN            1165..1167
FT                   /evidence="ECO:0007829|PDB:3LVP"
FT   HELIX           1168..1170
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   STRAND          1171..1174
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   HELIX           1176..1178
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   HELIX           1181..1186
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   HELIX           1191..1207
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   TURN            1212..1215
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   HELIX           1218..1226
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   HELIX           1239..1248
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   HELIX           1253..1255
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   HELIX           1259..1266
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   HELIX           1267..1269
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   HELIX           1274..1277
FT                   /evidence="ECO:0007829|PDB:1P4O"
FT   TURN            1279..1281
FT                   /evidence="ECO:0007829|PDB:3O23"
FT   TURN            1283..1285
FT                   /evidence="ECO:0007829|PDB:3LVP"
FT   STRAND          1286..1288
FT                   /evidence="ECO:0007829|PDB:1P4O"
SQ   SEQUENCE   1367 AA;  154793 MW;  AE8A735F87F745C8 CRC64;
     MKSGSGGGSP TSLWGLLFLS AALSLWPTSG EICGPGIDIR NDYQQLKRLE NCTVIEGYLH
     ILLISKAEDY RSYRFPKLTV ITEYLLLFRV AGLESLGDLF PNLTVIRGWK LFYNYALVIF
     EMTNLKDIGL YNLRNITRGA IRIEKNADLC YLSTVDWSLI LDAVSNNYIV GNKPPKECGD
     LCPGTMEEKP MCEKTTINNE YNYRCWTTNR CQKMCPSTCG KRACTENNEC CHPECLGSCS
     APDNDTACVA CRHYYYAGVC VPACPPNTYR FEGWRCVDRD FCANILSAES SDSEGFVIHD
     GECMQECPSG FIRNGSQSMY CIPCEGPCPK VCEEEKKTKT IDSVTSAQML QGCTIFKGNL
     LINIRRGNNI ASELENFMGL IEVVTGYVKI RHSHALVSLS FLKNLRLILG EEQLEGNYSF
     YVLDNQNLQQ LWDWDHRNLT IKAGKMYFAF NPKLCVSEIY RMEEVTGTKG RQSKGDINTR
     NNGERASCES DVLHFTSTTT SKNRIIITWH RYRPPDYRDL ISFTVYYKEA PFKNVTEYDG
     QDACGSNSWN MVDVDLPPNK DVEPGILLHG LKPWTQYAVY VKAVTLTMVE NDHIRGAKSE
     ILYIRTNASV PSIPLDVLSA SNSSSQLIVK WNPPSLPNGN LSYYIVRWQR QPQDGYLYRH
     NYCSKDKIPI RKYADGTIDI EEVTENPKTE VCGGEKGPCC ACPKTEAEKQ AEKEEAEYRK
     VFENFLHNSI FVPRPERKRR DVMQVANTTM SSRSRNTTAA DTYNITDPEE LETEYPFFES
     RVDNKERTVI SNLRPFTLYR IDIHSCNHEA EKLGCSASNF VFARTMPAEG ADDIPGPVTW
     EPRPENSIFL KWPEPENPNG LILMYEIKYG SQVEDQRECV SRQEYRKYGG AKLNRLNPGN
     YTARIQATSL SGNGSWTDPV FFYVQAKTGY ENFIHLIIAL PVAVLLIVGG LVIMLYVFHR
     KRNNSRLGNG VLYASVNPEY FSAADVYVPD EWEVAREKIT MSRELGQGSF GMVYEGVAKG
     VVKDEPETRV AIKTVNEAAS MRERIEFLNE ASVMKEFNCH HVVRLLGVVS QGQPTLVIME
     LMTRGDLKSY LRSLRPEMEN NPVLAPPSLS KMIQMAGEIA DGMAYLNANK FVHRDLAARN
     CMVAEDFTVK IGDFGMTRDI YETDYYRKGG KGLLPVRWMS PESLKDGVFT TYSDVWSFGV
     VLWEIATLAE QPYQGLSNEQ VLRFVMEGGL LDKPDNCPDM LFELMRMCWQ YNPKMRPSFL
     EIISSIKEEM EPGFREVSFY YSEENKLPEP EELDLEPENM ESVPLDPSAS SSSLPLPDRH
     SGHKAENGPG PGVLVLRASF DERQPYAHMN GGRKNERALP LPQSSTC
//
